New Canadian dyslipidemia guidelines now recommend monitoring C-reactive protein in some patients

New Canadian dyslipidemia guidelines now recommend monitoring C-reactive protein in some patients.

High sensitivity C-reactive protein (hs-CRP) will be used to determine whether to treat moderate-risk patients who DON'T have high cholesterol.

High-risk patients almost always get statins...and low-risk patients rarely do unless they have very high cholesterol.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote